Exagen Inc
XGN
Company Profile
Business description
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Contact
1261 Liberty Way
VistaCA92081
USAT: +1 760 560-1501
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
220
Stocks News & Analysis
stocks
Fears of deteriorating loan quality sends bank share plummeting
We maintain our fair value estimate despite unfavourable economic conditions.
stocks
Why it’s not all bad news for Flight Centre following downgrade
Despite an earnings downgrade, shares in FLT remain undervalued.
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.20 | 1.20 | -0.01% |
| CAC 40 | 8,353.16 | 78.45 | -0.93% |
| DAX 40 | 24,606.93 | 387.90 | -1.55% |
| Dow JONES (US) | 51,694.92 | 225.70 | -0.43% |
| FTSE 100 | 10,433.29 | 96.60 | -0.92% |
| HKSE | 22,671.86 | 405.05 | -1.76% |
| NASDAQ | 25,095.73 | 262.87 | -1.04% |
| Nikkei 225 | 69,360.88 | 3,005.46 | -4.15% |
| NZX 50 Index | 13,495.24 | 2.19 | 0.02% |
| S&P 500 | 7,310.31 | 47.18 | -0.64% |
| S&P/ASX 200 | 8,764.20 | 0.20 | 0.00% |
| SSE Composite Index | 4,027.26 | 93.02 | -2.26% |